Search Result

Results for "

MBC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Antibiotic (4) Apoptosis (6) Bacterial (17) Carbonic Anhydrase (1) ClpP (1) COX (1) Dengue Virus (1) DNA/RNA Synthesis (1) EGFR (1) ERK (3) Fungal (2) Isotope-Labeled Compounds (1) NF-κB (1) NO Synthase (1) Penicillin-binding protein (PBP) (1) PI3K (2) Reference Standards (3) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (17) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17587

4-Methylbenzylidene camphor 2 Publications Verification 4-MBC; Enzacamene	Apoptosis PI3K Akt ERK	Metabolic Disease
4-Methylbenzylidene camphor (4-MBC) is an endocrine disrupter that produces estrogen-like effects. 4-Methylbenzylidene camphor decreases the proliferation of human trophoblast cells and induces apoptosis. 4-Methylbenzylidene camphor activates PI3K/AKT and ERK1/2 signaling pathways and elevates intracellular ROS production. 4-Methylbenzylidene camphor is a ultraviolet (UV) filter and may hamper normal placental formation during early pregnancy .

HY-130187A

Sapienic acid sodium	Bacterial	Infection
Sapienic acid sodium is a fatty acid commonly found on the skin and in mucosa. Sapienic acid sodium has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid sodium is active against *Streptococcus sanguinis, Streptococcus mitis* and *Fusobacterium nucleatum* with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .

HY-107093

MBC-11	Apoptosis	Cancer
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research .

HY-107093B

MBC-11 triethylamine	Apoptosis	Cancer
MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research .

HY-107093A

MBC-11 trisodium	Apoptosis	Cancer
MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research .

HY-17587R

4-Methylbenzylidene camphor (Standard) 4-MBC (Standard); Enzacamene (Standard)	Reference Standards Apoptosis PI3K Akt ERK	Metabolic Disease
4-Methylbenzylidene camphor (Standard) is the analytical standard of 4-Methylbenzylidene camphor. This product is intended for research and analytical applications. 4-Methylbenzylidene camphor (4-MBC) is an endocrine disrupter that produces estrogen-like effects. 4-Methylbenzylidene camphor decreases the proliferation of human trophoblast cells and induces apoptosis. 4-Methylbenzylidene camphor activates PI3K/AKT and ERK1/2 signaling pathways and elevates intracellular ROS production. 4-Methylbenzylidene camphor is a ultraviolet (UV) filter and may hamper normal placental formation during early pregnancy .

HY-130187

Sapienic acid	Bacterial	Infection
Sapienic acid is a fatty acid commonly found on the skin and in mucosa. Sapienic acid has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid is active against *Streptococcus sanguinis, Streptococcus mitis* and *Fusobacterium nucleatum* with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively .

HY-P10362

Temporin-GHd	Bacterial	Infection
Temporin-GHd exhibits antibacterial activity against Streptococcus mutans (MIC=13.1 μM; *MBC*=26 μM). Temporin-GHd increases the permeability of the bacterial cell membrane, causing membrane damage and leakage of cellular contents. Temporin-GHd disrupts preformed biofilms at high concentrations. Temporin-GHd can bind to bacterial DNA, inhibiting DNA migration .

HY-RS18172

Dock2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dock2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dock2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dock2 Mouse Pre-designed siRNA Set A Dock2 Mouse Pre-designed siRNA Set A

HY-126046

ACP1b	ClpP Bacterial	Infection
ACP1b is an activator for ClpP protease with K_d of 3.2 μM, and exhibits antibacterial activity. ACP1b inhibits N. meningitidis and H. influenzae with *MBC* of 16 and 8 μg/mL .

HY-W016867

4-Chlorosalicylic acid	Fungal Bacterial	Infection
4-Chlorosalicylic acid is a pharmaceutical intermediate. Inhibits monophenolase and diphenolase activity with IC₅₀s of 1.89 mM and 1.10 mM. Potent antimicrobial activity. Against E. coli with the MIC of 250 μg/mL and with the MBC of 500 μg/mL.

HY-P10681

Crabrolin	Bacterial	Infection
Crabrolin is a tridecapeptide that can be extracted from the venom of the European hornet (Vespa crabro). Crabrolin shows MIC/MBC of 2/2, 16/64, 4/8 μM, for S. aureus (NCTC 10788), MRSA (NCTC 12493) and E. faecium (NTCC 12697), respectively .

HY-174459

Anti-MRSA agent 31	Bacterial Penicillin-binding protein (PBP)	Infection
Anti-MRSA agent 31 (Compound 6) is an *anti-methicillin-resistant Staphylococcus aureus* (MRSA) agent with a MIC of 97 μg/mL and a MBC of 781.25 μg/mL. Anti-MRSA agent 31 has a potent antibacterial activity and a strong Binding Protein 2a (PBP2a)** inhibitory activity .

HY-159960

Carbonic anhydrase inhibitor 28	Antibiotic Bacterial Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 28 (Compound 11) is a Pseudomonas aeruginosa carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 28 exhibits antimicrobial activity, with a MIC of 0.5 μg/mL and a *MBC* of 1 μg/mL against P. aeruginosa. Carbonic anhydrase inhibitor 28 can be used in anti-infection research .

HY-RS21233

Cacna1c Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cacna1c Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cacna1c gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cacna1c Mouse Pre-designed siRNA Set A Cacna1c Mouse Pre-designed siRNA Set A

HY-141632

Sphinganine-C17 Heptadecasphinganine	Bacterial	Infection Neurological Disease
Sphinganine-C17 (Heptadecasphinganine) is a synthetic bioactive sphingolipid and an isomer of sphinganine. Sphinganine-C17 inhibits the growth of Candida glabrata and Candida albicans with a minimum bactericidal concentration (MBC) of 0.5 μg/mL for both. Sphinganine-C17 can be used as an internal standard for the chromatographic analysis of sphingosine compounds .

HY-149534

DNA Gyrase-IN-9	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-9 (compound 4j) is an antibacterial agent that targets DNA gyrase. The MIC to inhibit Gram bacteria is 0.5-2 μg/mL, and the MBC to kill Gram bacteria is 2-8 μg/mL. DNA Gyrase-IN-9 inhibits DNA gyrase in Staphylococcus aureus with IC₅₀=6.29 μg/mL .

HY-100180R

Delpazolid (Standard) LCB01-0371 (Standard)	Reference Standards Bacterial Antibiotic	Infection
4-Chlorosalicylic acid (Standard) is the analytical standard of 4-Chlorosalicylic acid. This product is intended for research and analytical applications. 4-Chlorosalicylic acid is a pharmaceutical intermediate. Inhibits monophenolase and diphenolase activity with IC50s of 1.89 mM and 1.10 mM. Potent antimicrobial activity. Against E. coli with the MIC of 250 μg/mL and with the MBC of 500 μg/mL.

HY-W016867R

4-Chlorosalicylic acid (Standard)	Reference Standards Fungal Bacterial	Infection
4-Chlorosalicylic acid (Standard) is the analytical standard of 4-Chlorosalicylic acid. This product is intended for research and analytical applications. 4-Chlorosalicylic acid is a pharmaceutical intermediate. Inhibits monophenolase and diphenolase activity with IC50s of 1.89 mM and 1.10 mM. Potent antimicrobial activity. Against E. coli with the MIC of 250 μg/mL and with the MBC of 500 μg/mL.

HY-173225

MRSA/VRE-IN-1	Bacterial	Infection
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .

HY-130187S

Sapienic acid-d19	Isotope-Labeled Compounds Bacterial	Infection
Sapienic acid-d19 is a deuterated labeled Sapienic acid . Sapienic acid is a fatty acid commonly found on the skin and in mucosa. Sapienic acid has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid is active against *Streptococcus sanguinis, Streptococcus mitis* and *Fusobacterium nucleatum* with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively .

HY-168932

Antiangiogenic agent 8	Bacterial Antibiotic	Infection Cardiovascular Disease
Antiangiogenic agent 8 (Compound 3m) is an antibacterial agent with anti-angiogenic activity. The MIC values of Antiangiogenic agent 8 against E. coli, P. aeruginosa, B. subtilis, S. aureus, and C. glabrata are 16, 8, 4, 16, and 8 μg/mL, respectively, with *MBC* ranging from 32 to 64 μg/mL. Antiangiogenic agent 8 holds promise for applications in anti-infective therapy and cardiovascular disease research .

HY-174326

Antibacterial agent 282	Antibiotic Bacterial	Infection
Antibacterial agent 282 (Compound CP7), a seleno-Ciprofloxacin (HY-B0356) derivative, is an Antibacterial agent. Antibacterial agent 282 has significant antibacterial activity against gram-positive bacterium and gram-negative bacterium with MICs of 0.1-1.56 and 0.1-3.13 μg/mL, respectively (MBCs of 0.2-1.56 and 0.39-12.5 μg/mL). Antibacterial agent 282 potently disrupts and prevents biofilms formation of P. aeruginosa. Antibacterial agent 282 shows significant inhibitory activity towards the DNA gyrase from E. coli .

HY-P1633

Protegrin-1 PG1	Bacterial ERK COX NF-κB Apoptosis NO Synthase Dengue Virus	Infection Inflammation/Immunology
Protegrin-1 is an orally active antibacterial peptide. Protegrin-1 activates ERK, COX2, NFκB, inhibits Apoptosis, and NO production. Protegrin-1 has antibacterial activity against S. aureus, E. faecium, E. coli, P. aeruginosa and K. Pneumoniae, with MBC values between 10 and 20 µM. Protegrin-1 has antiviral activity against dengue NS2B-NS3. Protegrin-1 has anti-inflammatory activity. Protegrin-1 is used in the study of inflammatory diseases and infections .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library	2,624 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 2,624 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

2,624 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,624 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-P1633

Protegrin-1 PG1	Bacterial ERK COX NF-κB Apoptosis NO Synthase Dengue Virus	Infection Inflammation/Immunology
Protegrin-1 is an orally active antibacterial peptide. Protegrin-1 activates ERK, COX2, NFκB, inhibits Apoptosis, and NO production. Protegrin-1 has antibacterial activity against S. aureus, E. faecium, E. coli, P. aeruginosa and K. Pneumoniae, with MBC values between 10 and 20 µM. Protegrin-1 has antiviral activity against dengue NS2B-NS3. Protegrin-1 has anti-inflammatory activity. Protegrin-1 is used in the study of inflammatory diseases and infections .

HY-P10362

Temporin-GHd	Bacterial	Infection
Temporin-GHd exhibits antibacterial activity against Streptococcus mutans (MIC=13.1 μM; *MBC*=26 μM). Temporin-GHd increases the permeability of the bacterial cell membrane, causing membrane damage and leakage of cellular contents. Temporin-GHd disrupts preformed biofilms at high concentrations. Temporin-GHd can bind to bacterial DNA, inhibiting DNA migration .

HY-P10681

Crabrolin	Bacterial	Infection
Crabrolin is a tridecapeptide that can be extracted from the venom of the European hornet (Vespa crabro). Crabrolin shows MIC/MBC of 2/2, 16/64, 4/8 μM, for S. aureus (NCTC 10788), MRSA (NCTC 12493) and E. faecium (NTCC 12697), respectively .

Cat. No.	Product Name	Target	Research Area

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .

Cat. No.	Product Name	Chemical Structure

HY-130187S

Sapienic acid-d19
Sapienic acid-d19 is a deuterated labeled Sapienic acid . Sapienic acid is a fatty acid commonly found on the skin and in mucosa. Sapienic acid has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid is active against *Streptococcus sanguinis, Streptococcus mitis* and *Fusobacterium nucleatum* with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively .

Sapienic acid-d19

Sapienic acid-d19 is a deuterated labeled Sapienic acid . Sapienic acid is a fatty acid commonly found on the skin and in mucosa. Sapienic acid has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid is active against Streptococcus sanguinis, Streptococcus mitis and Fusobacterium nucleatum with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively .

Dock2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Dock2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dock2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cacna1c Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cacna1c Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cacna1c gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: